Ado-trastuzumab emtansine

恩美曲妥珠单抗

Report date: 2026/05/08 20:02:52
First In Class

Base Information

Drug NameAdo-trastuzumab emtansine
Drug Alias Name恩美曲妥珠单抗Trastuzumab-DM1198466Trastuzumab-mertansine赫赛莱Trastuzumab emtansine +[16] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2Tubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[15] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2013/02/22
Country/TerritoryCzechiaBahamasBelgium +[63] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteRoche Pharma AgChugai Pharmaceutical Co Ltd +[12] 
Inactive CompaniesInstitut Regional Du Cancer De MontpellierRoche Registration LtdUniversity Of Washington
Active IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[12] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsCholangiocarcinoma

Other Information

ATC CodeL01XC14
Related LinksWikipediaDrugBankKEGG